IndiaFilingsIndiaFilings
India FlagRegister India Company
UAE FlagRegister UAE Company
USA FlagRegister USA Company

POSILIVE PHARMACEUTICALS LLP

LLPIN : AAC-8330|ROC: RoC-BangaloreActive
Last Updated On : 13-01-2023
LLPINAAC-8330
LLP NamePOSILIVE PHARMACEUTICALS LLP
Number of Partners2
Number of Designated Partners2
ROC CodeRoC-Bangalore
Date of Incorporation21-10-2014
Registered AddressNo.227, 3rd Cross, 6th Stage 3rd Block, Chikkegowanapalya, Thalaghatt apura Bangalore Bangalore Karnataka 560062
Email ID[email protected]
Total Obligation of Contribution55,00,000
Main division of business activity to be carried out in India51
Description of main divisionWholesale trade and commission trade, except of motor vehicles and motorcycles
Date of last financial year end for Statement of Accounts and Solvency2022-03-31
Date of last financial year end for Annual Return filed31-03-2022
LLP StatusActive

Directors / Signatory Details

DIN / PANNameBegin Date
02558716HEDNA VISHNUMURTHY SANTHRUPTH21-10-2014
06957960RAGHAVENDRA JAYAKUMAR YENCHARLA21-10-2014
POSILIVE PHARMACEUTICALS LLP is a Limited Liability Partnership (LLP) governed by the LLP Act, 2008. Registered under the Registrar of Companies RoC-Bangalore, it operates as a non-government entity. According to the Ministry of Corporate Affairs (MCA), this LLP was incorporated on 21-10-2014 and last updated on 13-01-2023. Its LLP Identification Number (LLPIN) is , and the registration number is . Currently, its eFiling status is listed as “Active” as per MCA records.
From a financial standpoint, POSILIVE PHARMACEUTICALS LLP has a total contribution of INR 55,00,000. Details of the latest financial filings, such as the Statement of Accounts and Solvency or Annual Returns, are unavailable, indicating limited publicly disclosed financial data.
The registered office address is No.227, 3rd Cross, 6th Stage 3rd Block, Chikkegowanapalya, Thalaghatt apura Bangalore Bangalore Karnataka 560062. Correspondence or inquiries may be sent to the official email address, [email protected].
For those interested in further details, below are some frequently asked questions: